Erythrocyte membrane vesicles coated biomimetic and targeted doxorubicin nanocarrier: Development, characterization and in vitro studies

Guliz A. K. , Şanlıer Ş.

JOURNAL OF MOLECULAR STRUCTURE, vol.1205, 2020 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 1205
  • Publication Date: 2020
  • Doi Number: 10.1016/j.molstruc.2019.127664
  • Keywords: Doxorubicin, Magnetite, Biomimetic nanoparticles, Folate receptor, Targeted drug delivery, Ovarian cancer, IRON-OXIDE NANOPARTICLES, MAGNETITE NANOPARTICLES, OVARIAN-CANCER, DELIVERY


Ovarian cancer is the most common cause of death within gynecologic cancers and doxorubicin is an anthracycline agent, is widely used in many cancer types. Folate receptor enables of accumulation folate linked nanoparticles into tumor cells and magnetic targeting also provides localized addressing. The aim of this work is to develop a magnetic and biomolecularly targeted biomimetic doxorubicin nanocarrier system for ovarian cancer therapy. Firstly, highly dispersed starch and PEG diacid coated magnetic nanoparticles were synthesized with an easy and fabricable method and 91.45 +/- 1.07 mu g doxorubicin was adsorbed on per mg magnetic nanoparticles. The structure was verified with FTIR, TGA, VSM, TEM and zetasizer. Then, folate linked erythrocyte membrane vesicles were prepared from ghost cells and doxorubicin loaded magnetic nanoparticles were encapsulated into vesicles through extrusion due to enabling avoidance from immun clearance. The final nanocarrier system was nearly spherical in shape and had a hydrodynamic size of 157.4 +/- 33.2 nm. Drug release profile was determined as in a controlled manner and IC50 value against SKOV3 for 72 h was calculated as 0.74 +/- 0.32 mg/mL which was lower than that of free doxorubicin. In conclusion, it was suggested that biomimetic doxorubicin nanocarrier system have many advantages for targeted ovarian cancer therapy. (C) 2019 Elsevier B.V. All rights reserved.